Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

cites work (P2860)

Q38698520	Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence
Q58023660	Akute Leukämien des Erwachsenen
Q36568589	Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario
Q36984852	Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia
Q37738589	Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemia
Q37470879	An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia
Q92479171	Approach to the Adult Acute Lymphoblastic Leukemia Patient
Q42336338	BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors.
Q34929425	Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker
Q37774915	Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
Q33580572	Changing therapy from Glivecto a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
Q41594071	Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop
Q33587563	Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
Q38194585	Current and future management of Ph/BCR-ABL positive ALL.
Q47710825	Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults
Q37650203	Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Q37376595	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL
Q41863632	Dasatinib for a child with Philadelphia chromosome-positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy
Q58703906	Dasatinib monotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia with pulmonary infection in induction remission: A case report and review of the literature
Q92158098	Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia
Q42096217	Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.
Q56974816	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t
Q41724569	Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia
Q38207017	Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus
Q52563633	Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Q33843477	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
Q33379060	Five donors-one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord-blood and third-party donors
Q36201257	Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study
Q36960525	Imatinib mesylate in the treatment of hematologic malignancies
Q40817830	Management of Philadelphia chromosome-positive acute lymphoblastic leukemia
Q33762835	Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.
Q57301411	Management of older adults with acute lymphoblastic leukemia: challenges & current approaches
Q39112294	Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia
Q35550090	Mutational spectrum of adult T-ALL
Q43014298	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following All
Q38752449	New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Q37738486	New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia
Q37836938	New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia
Q38023947	Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.
Q37931235	Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly
Q90463804	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia
Q64064226	Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission
Q36029619	Outcomes after induction failure in childhood acute lymphoblastic leukemia
Q37632798	Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
Q37851951	Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults
Q37613888	Philadelphia chromosome-positive acute lymphoblastic leukemia
Q37810967	Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options
Q38044901	Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy
Q57093731	Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic l
Q54330255	Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Q33412662	Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International
Q46341511	Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
Q37353919	Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
Q26799954	Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia
Q33395138	Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy
Q91915097	Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry
Q34557165	Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis
Q38759431	The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies
Q39643630	The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells
Q35087291	The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells
Q38375425	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia
Q64243914	Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma
Q64097232	Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
Q47774455	Treatment of Older Patients with Acute Lymphoblastic Leukaemia
Q37657483	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
Q38087930	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
Q37152745	Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
Q37244701	Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Q45395583	Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol
Q38787763	Treatment of older patients with acute lymphoblastic leukemia.
Q43175147	Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia
Q38739574	Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives
Q53365037	[Acute leukemia in adults].
Q88665500	[Chinese guidelines for diagnosis and treatment of acute lymphoblastic leukemia(2016)]

P356	DOI	10.1002/CNCR.22631
P698	PubMed publication ID	17429836

P50	author	Aristoteles A N Giagounidis	Q71785823
P2093	author name string	Dieter Hoelzer
		Matthias Stelljes
		Ulrich Dührsen
		Marc Schmalzing
		Heike Pfeifer
		Anja Binckebanck
		Lydia Wunderle
		Barbara Wassmann
		Oliver G. Ottmann
P2860	cites work	BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study	Q45712588
		High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group	Q46847866
		Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.	Q52958934
		Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.	Q54574746
		Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study	Q56997440
		Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)	Q58414415
		Acute lymphoblastic leukemia in the elderly	Q68551522
		Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia	Q73399572
		Prognostic factors in elderly acute lymphoblastic leukaemia	Q73476169
		Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias	Q28246193
		Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL	Q28246204
		Overriding imatinib resistance with a novel ABL kinase inhibitor	Q30014844
		Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome	Q33336718
		A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias	Q33343973
		Philadelphia chromosome-positive acute lymphocytic leukemia	Q34189733
		Acute lymphoblastic leukemia in the elderly	Q34976235
		Management of acute lymphoblastic leukemia in older patients	Q36449627
		Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.	Q40458599
		Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia	Q40543180
		Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients	Q40671094
		Acute lymphocytic leukemia (ALL) in elderly patients	Q40717244
		Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib	Q43473669
		Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation	Q43893091
		Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).	Q44189698
		Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia	Q44381170
		Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment	Q44582795
		Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate	Q44612967
		A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia	Q44675415
P433	issue	10
P407	language of work or name	English	Q1860
P921	main subject	leukemia	Q29496
		imatinib	Q177094
		patient	Q181600
		cancer research	Q3421914
		chemotherapy	Q974135
		Philadelphia chromosome	Q1129111
		lymphoblastic leukemia	Q18553852
P304	page(s)	2068-2076
P577	publication date	2007-01-01
P1433	published in	Cancer	Q326041
P1476	title	Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)
P478	volume	109

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

Reverse relations